Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BSGM Biosig Technologies	$5.18 +3.8%	$5.99	$0.23 ▼ $14.11	$162.75M	1.65	702,332 shs	508,600 shs
ELMD Electromed	$20.27 +6.6%	$19.64	$13.74 ▼ $35.56	$169.98M	0.38	82,029 shs	50,766 shs
NEPH Nephros	$4.18 +4.0%	$3.80	$1.36 ▼ $5.00	$44.31M	1.11	27,499 shs	56,545 shs
TLSI TriSalus Life Sciences	$5.05 +1.8%	$4.74	$3.42 ▼ $5.88	$191.09M	0.48	63,826 shs	166,429 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BSGM Biosig Technologies	+5.72%	-2.16%	-18.20%	-5.49%	+1,034.09%
ELMD Electromed	-3.01%	-0.78%	+1.77%	-3.21%	+28.95%
NEPH Nephros	-1.47%	+0.50%	+14.53%	+37.67%	+117.30%
TLSI TriSalus Life Sciences	-3.13%	+27.84%	+10.22%	-10.79%	-10.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BSGM Biosig Technologies	1.9427 of 5 stars	3.5	0.0	0.9	1.7	0.6
ELMD Electromed	1.8248 of 5 stars	2.0	3.0	2.3	1.7	1.3
NEPH Nephros	1.5102 of 5 stars	3.5	3.0	0.0	0.8	0.0
TLSI TriSalus Life Sciences	3.054 of 5 stars	3.6	3.0	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BSGM Biosig Technologies	3.00	Buy	$10.00	91.94% Upside
ELMD Electromed	4.00	Strong Buy	$33.50	66.25% Upside
NEPH Nephros	3.00	Buy	$5.50	30.33% Upside
TLSI TriSalus Life Sciences	3.25	Buy	$10.75	111.16% Upside

Current Analyst Ratings Breakdown

Latest NEPH, TLSI, BSGM, and ELMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	NEPH Nephros	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.50 ➝ $6.00
7/22/2025	ELMD Electromed	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$29.00
7/21/2025	ELMD Electromed	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/6/2025	BSGM Biosig Technologies	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$2.50 ➝ $10.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BSGM Biosig Technologies	$40K	4,092.46	N/A	N/A	($0.11) per share	-47.36
ELMD Electromed	$61.44M	2.75	$0.49 per share	41.36	$5.10 per share	3.95
NEPH Nephros	$14.16M	3.16	$0.02 per share	203.89	$0.91 per share	4.64
TLSI TriSalus Life Sciences	$29.43M	6.55	N/A	N/A	($0.51) per share	-9.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BSGM Biosig Technologies	-$10.33M	N/A	0.00	N/A	N/A	N/A	-10,930.60%	-90.03%	N/A
ELMD Electromed	$5.15M	$0.79	26.87	∞	N/A	11.34%	15.71%	13.37%	N/A
NEPH Nephros	$70K	$0.12	35.17	∞	N/A	7.95%	14.89%	11.64%	11/6/2025 (Estimated)
TLSI TriSalus Life Sciences	-$30.05M	-$1.18	N/A	N/A	N/A	-86.61%	N/A	-116.50%	N/A

Latest NEPH, TLSI, BSGM, and ELMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q2 2025	BSGM Biosig Technologies	-$0.04	-$0.74	-$0.70	-$0.74	N/A	N/A
8/12/2025	Q2 2025	TLSI TriSalus Life Sciences	-$0.22	-$0.27	-$0.05	-$0.27	$10.69 million	$11.21 million
8/7/2025	Q2 2025	NEPH Nephros	-$0.0250	$0.02	+$0.0450	$0.02	$3.60 million	$4.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BSGM Biosig Technologies	N/A	N/A	N/A	N/A	N/A
ELMD Electromed	N/A	N/A	N/A	N/A	N/A
NEPH Nephros	N/A	N/A	N/A	N/A	N/A
TLSI TriSalus Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BSGM Biosig Technologies	N/A	0.03	2.37
ELMD Electromed	N/A	5.10	4.74
NEPH Nephros	N/A	5.41	4.14
TLSI TriSalus Life Sciences	N/A	4.08	3.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BSGM Biosig Technologies	7.16%
ELMD Electromed	40.82%
NEPH Nephros	41.10%
TLSI TriSalus Life Sciences	2.58%

Insider Ownership

Company	Insider Ownership
BSGM Biosig Technologies	24.80%
ELMD Electromed	14.00%
NEPH Nephros	6.70%
TLSI TriSalus Life Sciences	27.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BSGM Biosig Technologies	50	31.42 million	23.63 million	No Data
ELMD Electromed	160	8.39 million	7.36 million	Optionable
NEPH Nephros	30	10.60 million	9.89 million	Not Optionable
TLSI TriSalus Life Sciences	106	37.84 million	27.43 million	Not Optionable

NEPH, TLSI, BSGM, and ELMD Headlines

Recent News About These Companies

Roth Capital Issues Optimistic Outlook for TLSI Earnings

August 19 at 2:39 AM | marketbeat.com

What is Roth Capital's Estimate for TLSI Q3 Earnings?

August 19 at 2:16 AM | americanbankingnews.com

FY2025 EPS Estimates for TLSI Raised by Cantor Fitzgerald

August 17, 2025 | marketbeat.com

Northland Capmk Has Bearish Forecast for TLSI Q3 Earnings

August 17, 2025 | marketbeat.com

Northland Capmk Brokers Reduce Earnings Estimates for TLSI

August 17, 2025 | americanbankingnews.com

FY2025 EPS Estimates for TLSI Boosted by Cantor Fitzgerald

August 16, 2025 | americanbankingnews.com

TriSalus Life Sciences (NASDAQ:TLSI) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS

August 14, 2025 | marketbeat.com

TriSalus Life Sciences Reports Strong Growth Amid Challenges

August 14, 2025 | msn.com

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q2 2025 Earnings Call Transcript

August 14, 2025 | msn.com

TriSalus Life Sciences Reports Strong Q2 2025 Growth

August 13, 2025 | msn.com

TriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

TriSalus Life Sciences backs FY25 revenue growth view up 50%

August 12, 2025 | msn.com

TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates

August 12, 2025 | zacks.com

TriSalus Life Sciences (TLSI) Expected to Announce Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

July 30, 2025 | businesswire.com

TriSalus Life Sciences (NASDAQ:TLSI) Stock Price Down 4.6% - Should You Sell?

July 30, 2025 | marketbeat.com

TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call

July 29, 2025 | businesswire.com

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock

July 24, 2025 | businesswire.com

TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Business Wire

June 25, 2025 | businesswire.com

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

June 23, 2025 | businesswire.com

TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

May 30, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH, TLSI, BSGM, and ELMD Company Descriptions

Biosig Technologies NASDAQ:BSGM

$5.18 +0.19 (+3.81%)

Closing price 04:00 PM Eastern

Extended Trading

$5.20 +0.02 (+0.29%)

As of 06:18 PM Eastern

BioSig Technologies, Inc., together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

Electromed NYSE:ELMD

$20.27 +1.25 (+6.57%)

Closing price 04:00 PM Eastern

Extended Trading

$20.45 +0.18 (+0.91%)

As of 06:10 PM Eastern

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

Nephros NASDAQ:NEPH

$4.18 +0.16 (+3.98%)

Closing price 04:00 PM Eastern

Extended Trading

$4.18 0.00 (0.00%)

As of 04:10 PM Eastern

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

TriSalus Life Sciences NASDAQ:TLSI

$5.05 +0.09 (+1.81%)

Closing price 04:00 PM Eastern

Extended Trading

$5.07 +0.02 (+0.30%)

As of 04:29 PM Eastern

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time